Decoding Your Pathology Report and Risk Level

When you receive a pathology report for prostate cancer, you are looking at the most critical “map” of your disease. This document describes the appearance of your cancer cells under a microscope and provides the data doctors use to predict how the cancer might behave.

The Gleason Score and Grade Groups

For decades, the Gleason Score has been the standard for grading prostate cancer. Pathologists assess the architectural patterns of the cells. Importantly, patterns 1 and 2 are no longer assigned in modern biopsy reporting. A pathologist identifies the most common (primary) pattern and the second most common (secondary) pattern, assigning each a number from 3 to 5. These are added together to create your score (e.g., 3+4=7) ^[1].

Today, doctors rely heavily on ISUP Grade Groups (1–5), which make these scores easier to understand and more clinically accurate ^[2]:

• Grade Group 1 (Gleason 3+3=6): The cells look closest to healthy prostate tissue. This is the least aggressive form.
• Grade Group 2 (Gleason 3+4=7): The primary pattern is 3, but a secondary pattern of 4 is present.
• Grade Group 3 (Gleason 4+3=7): The primary pattern is 4. This is a critical distinction—Grade Group 3 is significantly more aggressive than Grade Group 2 ^[3][4].
• Grade Group 4 (Gleason 8): Includes scores like 4+4, 3+5, or 5+3. These cells grow aggressively.
• Grade Group 5 (Gleason 9–10): The most aggressive form; the cells have lost almost all their normal structure ^[1].

Additional Pathology Features

Beyond the Grade Group, a genitourinary pathologist integrates other microscopic features to complete the risk picture:

• Cribriform Pattern: Cancer cells forming a “sieve-like” appearance. This is generally a pattern-4 adverse feature associated with a higher risk of the cancer spreading ^[5][6].
• Intraductal Carcinoma (IDC-P): Cancer cells growing inside the existing ducts of the prostate. When found alongside invasive cancer, it is a marker for more aggressive disease ^[7][8].
• Percentage of Pattern 4: In Grade Groups 2 or 3, the report should note what percentage of the tumor is “pattern 4.” A higher percentage generally suggests a higher risk ^[9][10].
• Perineural Invasion (PNI): Cancer seen tracking along nerve fibers within the prostate. This is a common finding that does not automatically mean the cancer has spread outside the gland, but is factored into your overall risk ^[11].

(Note: Features like cribriform or IDC-P do not automatically dictate a specific “intensive” treatment on their own; they must be interpreted alongside your full clinical picture.)

Staging the Cancer (Clinical TNM)

While “grading” tells us how aggressive the cells look, staging estimates the physical extent of the cancer. A needle biopsy alone cannot establish the full stage; doctors combine exams, biopsies, and imaging (like MRI or PSMA PET) to assign a clinical stage ^[12]:

• T (Tumor): Estimates local extent.
  • T1: The tumor cannot be felt or seen on imaging (found via elevated PSA/biopsy). It has clinically important subcategories.
  • T2: The tumor is confined to the prostate (with substages indicating how much of one or both sides is involved).
  • T3: Cancer has broken through the prostate capsule (extraprostatic extension) or invaded the seminal vesicles.
  • T4: Cancer has invaded adjacent structures like the bladder or rectum.
• N (Nodes): Assesses regional lymph nodes.
• M (Metastasis): M0 means no distant spread; M1 means it has spread to non-regional lymph nodes, bones, or other distant organs.

The NCCN Risk Framework (Simplified Summary)

To help guide treatment, the National Comprehensive Cancer Network (NCCN) combines your PSA, Grade Group, and clinical stage into “Risk Groups.” Note: This is a simplified summary. Your clinician must combine all exact factors, as a single variable can shift your category. ^[13]:

Completeness Checklist

When you review your pathology report, look for these data points. If any are missing, ask your doctor:

1. Gleason Score and ISUP Grade Group (1–5) ^[2].
2. Number of Cores: How many tissue samples were taken and how many contain cancer ^[16].
3. Tumor Extent: The percentage or millimeter length of cancer in each core ^[2].
4. Percentage Pattern 4: For Grade Groups 2 and 3 ^[2].
5. Adverse Features: Explicit mention of cribriform pattern or intraductal carcinoma ^[17].
6. Perineural Invasion (PNI): Present or absent ^[11].